LY-2090314

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameLY-2090314
Drug Alias NameGSK3 inhibitor Eli LillyLY-2090314
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsPancreatic NeoplasmsLeukemiaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsLeukemiaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A